Equities researchers at Zacks Research issued their FY2027 EPS estimates for shares of Intellia Therapeutics in a research note issued to investors on Thursday, March 20th. Zacks Research analyst R.

NEW YORK, NY / ACCESS Newswire / March 23, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to ...

If you suffered losses exceeding $50,000 in Intellia between July 30, 2024 and January 8, 2025 and would like to discuss your ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Analysts are intrested in these 5 stocks: ( ($PLTR) ), ( ($GOLD) ), ( ($INTU) ), ( ($NTLA) ) and ( ($BYON) ). Here is a breakdown of their recent ...

Using CRISPR/Cas9 gene-editing technology, Intellia Therapeutics develops gene-editing treatments for genetic diseases. The company's lead programs, NTLA-2001 and NTLA-2002, target transthyretin ...

Intellia Therapeutics details progress in Phase 3 trials for NTLA-2002 and nex-z, anticipating key regulatory submissions by 2026. Intellia Therapeutics has announced the initiation of the global ...

Intellia Therapeutics NTLA incurred a fourth-quarter 2024 loss of $1.24 per share (excluding one-time expenses of change in fair value of investments), which was narrower than the Zacks Consensus ...

CAMBRIDGE, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ...

Intellia Therapeutics (NASDAQ:NTLA), a leader in gene-editing technology, delivered its fourth-quarter earnings results on Feb. 27. The company reported a net loss of $1.27 per share, which was ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...